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Aims To investigate myocardial fibrosis (MF) in a large series of severe aortic stenosis (AS) patients using invasive biopsy
and non-invasive imaging.
...................................................................................................................................................................................................
Methods and
results
One hundred thirty-three patients with severe, symptomatic AS accepted for surgical aortic valve replacement
underwent cardiovascular magnetic resonance (CMR) with late gadolinium enhancement (LGE) and extracellular
volume fraction (ECV) quantification. Intra-operative left ventricular (LV) biopsies were performed by needle or
scalpel, yielding tissue with (n= 53) and without endocardium (n= 80), and compared with 10 controls. Myocardial
fibrosis occurred in three patterns: (i) thickened endocardium with a fibrotic layer; (ii) microscopic scars, with a
subendomyocardial predominance; and (iii) diffuse interstitial fibrosis. Collagen volume fraction (CVF) was elevated
(P< 0.001) compared with controls, and higher (P< 0.001) in endocardium-containing samples with a decreasing
CVF gradient from the subendocardium (P= 0.001). Late gadolinium enhancement correlated with CVF (P< 0.001)
but not ECV. Both LGE and ECV correlated independently (P< 0.001) with N-terminal pro-brain natriuretic pep-
tide and high-sensitivity-troponin T. High ECV was also associated with worse LV remodelling, left ventricular ejec-
tion fraction and functional capacity. Combining high ECV and LGE better identified patients with more adverse LV
remodelling, blood biomarkers and histological parameters, and worse functional capacity than each parameter
alone.
...................................................................................................................................................................................................
Conclusion Myocardial fibrosis in severe AS is complex, but three main patterns exist: endocardial fibrosis, microscars (mainly
in the subendomyocardium), and diffuse interstitial fibrosis. Neither histological CVF nor the CMR parameters ECV
and LGE capture fibrosis in its totality. A combined, multi-parametric approach with ECV and LGE allows best
stratification of AS patients according to the response of the myocardial collagen matrix.
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Introduction
In aortic stenosis (AS), patient symptoms and outcome are deter-
mined by the severity of the valve stenosis, but also by the myocardial
response to the generated afterload—a process that appears crucial,
but is incompletely understood.1 Our scientific exploration of this
uses two main approaches. Clinically, the myocardium is measured
by assessing structure and function using imaging [echocardiography,
cardiovascular magnetic resonance (CMR)].2 Pathophysiologically,
the myocardium is assessed histologically on tissue samples. It is be-
lieved that a complex interplay of cellular changes (including hyper-
trophy and cell death by apoptosis or autophagy), microvascular
ischaemia, and alterations of the extracellular matrix occurs with final
common pathways leading to myocardial fibrosis (MF). Most of the
evidence for this has been from a few small biopsy or autopsy studies.
Whereas autopsy descriptions of MF can provide a global view, in in
vivo studies, sampling is limited by biopsy size, and fibrosis is typically
described only by the quantity of collagen deposition [collagen vol-
ume fraction (CVF)]. However, histological analysis of heart tissue
also allows differentiation of fibrosis subtypes based on location and
morphological characteristics of collagen deposits (focal microscopic
scars, diffuse interstitial and perivascular strands; see Supplementary
material online, Figure S1), with the functional impact of MF not only
depending on the amount of collagen tissue but also on the charac-
teristics of collagen deposits.3 Although new insights are being gener-
ated by imaging tissue characterization [the late gadolinium
enhancement (LGE) technique permits quantification of focal intersti-
tial expansion,4–8 and diffuse interstitial expansion can be measured
by extracellular volume fraction (ECV)9–12], the histological basis of
LGE and ECV in AS and their association with fibrosis subtypes are
only partly understood.
We investigated myocardial fibrosis in a large series of symptomatic
severe AS patients using invasive biopsy and non-invasive imaging. We
simultaneously and at scale assessed cardiac status by measuring func-
tional capacity and blood biomarkers (cardiomyocyte stress/damage
markers), by imaging structure and function (echocardiography and
CMR), and by performing non-invasive (ECV and LGE) and histologi-
cal (fibrosis location, pattern, and CVF) tissue characterization.
Methods
Study cohort
A single centre, prospective observational cohort study at University
College London Hospital NHS Trust between January 2012 and January
2015 of patients with severe, symptomatic AS undergoing surgical aortic
valve replacement (AVR) with or without coronary artery bypass grafting
(CABG) using invasive and non-invasive assessment. The study was ap-
proved by the ethical committee of UK National Research Ethics Service
(07/H0715/101) and was performed as a planned sub-study of RELIEF-AS
(ClinicalTrials.gov NCT02174471). The study conformed to the principles
of the Helsinki Declaration, and all subjects gave written consent to partic-
ipate. Patients were recruited prior to pre-operative assessment and
underwent clinical assessment with clinical history, blood pressure, 6-min-
ute-walk test (6MWT), blood sampling [for haematocrit, renal function,
N-terminal pro-brain natriuretic peptide (NT-proBNP) and high sensitivity
troponin T (hs-TnT)], transthoracic echocardiogram, and CMR.
Inclusion criteria: patients undergoing AVR ± CABG for severe AS (two
or more of: AVA <1 cm2, pressure gradient >_64 mmHg (peak)/
>_40 mmHg (mean), velocity time integral (VTI) ratio <0.25 or reclassifica-
tion of discordant echocardiographic data to severe by alternate modality);
consenting for study protocol; age >18 years, ability to undergo CMR scan.
Exclusion criteria: pregnancy/breastfeeding, estimated glomerular fil-
tration rate <30 mL/min, CMR incompatible devices, previous valve sur-
gery, infective endocarditis, severe valve disease other than AS or other
planned concurrent valve operations (severe AS with mild or moderate
AR was acceptable).
Control myocardial samples were obtained from autopsies of 10 sub-
jects (7 male, 3 female; all Caucasian, age: 60 ± 7 years) who died of non-
cardiovascular causes showing no signs of macroscopic or microscopic
cardiac lesions.
Cardiac imaging
Echocardiography assessed diastolic function and valve area/velocities
(with CMR for regurgitant volumes if needed).13 Cardiovascular magnetic
resonance assessed structure, function and myocardial tissue character-
ization. Echocardiography used a GE Vivid E9 system (GE Healthcare,
Wauwatosa, USA) with a 4-MHz transducer as per current guidelines.
Cardiovascular magnetic resonance was performed at 1.5 Tesla
(Magnetom Avanto, Siemens Medical Solutions) with 32 channel cardiac
coil arrays, using a standard clinical scan protocol with LGE imaging and T1
mapping prior to and after bolus gadolinium contrast [0.1 mmol/kg of
Gadoterate meglumine (gadolinium-DOTA, marketed as Dotarem,
Guerbet S.A., Paris, France)]. Post-contrast imaging was performed at
10 min (LGE) and 15 min (T1 mapping). The T1 mapping sequence used
was a balanced-SSFP-based MOdified Look-Locker Inversion Recovery
(MOLLI) variants (investigational prototypes) with motion-correction
(sampling scheme pre-contrast 5s(3s)3s and post-contrast 4s(1s)3s(1s)2s;
system software version VB17).14
Image analysis
Cardiovascular magnetic resonance imaging analysis was performed using
CVI42 software (Version 5.1.2[303], Calgary, Canada) blinded to clinical
parameters. Left ventricular volume and mass analysis were performed
by manual contouring of the endo- and epicardial borders at end-diastole
and end-systole with papillary muscle and trabeculations included in the
LV mass. Late gadolinium enhancement was quantified in grams and per-
centage of LV mass using a 3 standard deviations (SD) threshold. For T1
mapping, three short axis T1 maps (base, mid, and apex) were manual
contoured for endo- and epicardial borders. Partial voluming of blood
was minimized by an automatic 10% offset from the endo- and epicardial
border (see Supplementary material online, Figure S2). Segments with
infarct-pattern LGE (subendocardial LGE) were excluded from ECV anal-
ysis but non-infarct LGE was included (as per guidelines). Extracellular
volume fraction was defined as ECV = (1-Hct) [DR1myocardium]/
[DR1blood].
15 Normal ranges have been described previously.16
Histomorphological studies
Biopsies were harvested under direct vision from the basal anteroseptum
when the native valve was removed by one of six surgeons using either a
14-gauge coaxial needle system (Temno evolution, Carefusion, USA) or a
surgical scalpel, as per surgeon’s choice (as per ethics) and fixed in 10%
buffered formalin and embedded in paraffin. Histological analysis was per-
formed blinded to clinical and imaging data. For MF, the fraction of myo-
cardial volume with positive staining for collagen, CVF, was determined
by quantitative morphometry (Cellˆ D, Olympus Soft imaging Solutions
GmbH, Mu¨nster, Germany) in sections stained with collagen-specific pic-
rosirius red. All available myocardial tissue was analysed (average area
was 5.21 ± 3.62 mm2/sample).9 Endocardial thickness was quantified as
the mean value of 5–15 measurements.
2 T.A. Treibel et al.
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Statistical analyses used SPSS 22 (IBM, Armonk, NY, USA). Continuous
variables were expressed as mean ± SD, categorical as percentages.
Normality was checked using the Shapiro–Wilk test. Groups were com-
pared using independent-samples t-test (if normal) or the Mann–Whitney
U (if non-normal), and the v2 test for binomial variables. Correlations
were estimated by using the Pearson correlation coefficient once normal-
ity was demonstrated; otherwise, the Spearman correlation coefficient.
Log transformation was applied to normalize NT-proBNP and hs-TnT.
The influence of potential confounding factors [age, gender, history of
coronary artery disease (CAD)] used multivariate linear regression analy-
sis. The unstandardized coefficient B and its 95% confidence interval were
recorded. A two-sided P-value of <0.05 was considered significant.
Results
Baseline characteristics
One hundred and forty-four patients with severe, symptomatic AS under-
went CMR prior to and myocardial biopsy at the time of AVR. Eleven pa-
tients were excluded due to inability to complete CMR [claustrophobia
(n= 2), haemodynamic instability (n= 1)], incomplete CMR dataset
(n= 1), or significant bystander disease known to affect LV remodelling
and outcome (cardiac amyloidosis n= 6; Fabry Disease n= 1).17
One hundred thirty-three patients were included (age
70 ± 10 years, 56% male, AVAi 0.41 ± 0.13 cm2/m2, Vmax 4.3 ± 0.6 m/
s, mean gradient 46 ± 13 mmHg); all but 6 patients were symptomatic
(96%) with dyspnoea (80%), chest pain (32%), and/or syncope (8%).
Aetiology of AS was predominantly tricuspid (71%) with the
.................................................................................................
Table 1 Baseline characteristics
Total
n, male (%) 133 (56%)
Age (years) 70.3 ± 9.6
BMI (kg/m2) 28.3 ± 5.1
Co-morbidities
Hypertension 101 (76%)
SBP (mmHg) 134 ± 18
DBP (mmHg) 76 ± 11
Diabetes 28 (21%)
Coronary artery disease 45 (34%)
Symptoms (yes/no) 127/6
NYHA functional class I, II, III, IV 26, 62, 41, 4
Chest pain 43 (32%)
Syncope 11 (8%)
Six-minute walk test distance (m; median IQR) 458 (318–572)
Risk scores
STS % (median IQR) 1.5 (1.0–2.4)
EuroScoreII % (median IQR) 1.6 (1.0–2.5)
Type of valve
Tricuspid 95 (71%)
Bicuspid 37 (28%)
Unicuspid 1
Echocardiography
Vmax (m/s) 4.3 ± 0.6
Peak gradient (mmHg) 75 ± 19
Mean gradient (mmHg) 46 ± 13
AVAi (cm2/m2) 0.41 ± 0.13
Diastolic function
E-wave 0.85 ± 0.29
E deceleration time (ms) 237 ± 75
E/e’ ratio 13.7 ± 6.1
PASP (mmHg) 31 ± 8
CMR parameters
EDVi (mL/m2) 66 ± 22
ESVi (mL/m2) 22 ± 19
LVMi (g/m2) 87 ± 24
LVEF (%) 70 ± 15
SVi (mL/m2) 44 ± 11
CI (L/min/m2) 3.2 ± 0.7
Maximal wall thickness (mm) 14 ± 3
LAAi (cm2/m2) 13.5 ± 3.9
CMR flow
Aortic regurgitant fraction in %, median IQR 10.9 (3.3–24.3)
Mitral regurgitant fraction in %, median IQR 4.0 (0–20.5)
Late gadolinium enhancement
3SD method in grams, median IQR 10.5 (6.0–20.3)
T1 mapping (MOLLI)
T1 myocardium (native in ms) 1043 ± 44
ECV (%) 28.4 ± 2.9
Histology
Collagen volume fraction (%) 11.5 ± 8.6
Endocardial thickness (lm) 228 ± 129
Continued
.................................................................................................
Table 1 Continued
Total
Drug history
ACE-I/ARB 60 (45%)
Betablocker 45 (34%)
Statin 86 (65%)
Aspirin 54 (41%)
Spironolactone 3 (2%)
Blood
NT-pro-BNP (pg/mL) (median IQR) 72 (29–242)
hs-Troponin T (ng/L) (median IQR) 13 (8–19)
Creatinine (micromol/L) 85 ± 26
eGFR (mL/min/1.73m2) 77 ± 22
Haematocrit (%) 40.0 ± 4.2
BSA, body surface area; SBP, systolic blood pressure; DBP, diastolic blood pres-
sure; NYHA, New York Heart Association; IQR, interquartile range; STS, Society
of Thoracic Surgeons’ risk model score; EuroScoreII, European System for
Cardiac Operative Risk Evaluation II score; Vmax, peak velocity through the aor-
tic valve; AVAi, aortic valve area index; E, peak early velocity of the transmitral
flow; E, peak early diastolic velocity of the mitral annulus displacement; PASP, pul-
monary artery systolic pressure measured by echocardiography; EDVi, end-dia-
stolic volume index; ESVi, end-systolic volume index; LVMi, left ventricular mass
index; LVEF, left ventricular ejection fraction; SVi, stroke volume index; CI, car-
diac output indexed; LAAi, left atrial area index; 3SD, three standard deviations;
ECV, extracellular volume; ACE-I, angiotensin-converting-enzyme inhibitor; ARB,
angiotensin-receptor blocker; NT-proBNP, N-terminal pro-brain natriuretic pep-
tide; hs-TnT, high sensitivity troponin T; eGFR, estimated glomerular filtration
rate; CMR, cardiovascular magnetic resonance.
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.remainder bicuspid (28%) or unicuspid AS (n= 1). The treatment re-
ceived was tissue or mechanical valve replacement in 71% and 29%, re-
spectively, with additional bypass grafting in 23% and aortic
intervention in 6%. Baseline characteristics are shown in Table 1.
Representative images of the AS severity by echocardiography (con-
tinuous-wave Doppler), LV remodelling (SSFP-cine short axis), and MF
by CMR (LGE and ECV) and histology (CVF) are shown in Figure 1.
Non-invasive assessment by
cardiovascular magnetic resonance
Focal fibrosis, measured by LGE, was commonly seen, affecting 71%
of men and 46% of women, with a similar split in infarct-like pattern
vs. non-infarct pattern LGE (males 16% vs. 59%; females 17% vs.
37%—some had both). The location of non-infarct LGE was right
ventricular insertion point (60%), patchy focal (26%), papillary muscle
(19%), and/or mid-myocardial (18%) (see Supplementary material
online, Figure S2). Mean enhanced LV myocardial mass was
14.3 ± 11.2 g (median 10.5 g; interquartile range 6.0–20.3 g). Mean
ECV was 28.4 ± 2.9%. Imaging findings are summarized in Table 1.
Invasive assessment by biopsy
Collagen volume fraction was elevated in severe AS (11.5 ± 8.6% vs.
1.95 ± 0.20% controls, P< 0.001) and was higher in men than in
women (12.9 ± 8.8 vs. 9.9 ± 8.0%, P= 0.030). There were 53 myocar-
dial biopsies with endocardium (mostly from scalpel biopsies, 60%)
and 80 samples with no identifiable endocardium. Biopsies with
Figure 1 Aortic stenosis, myocardial hypertrophy and fibrosis by imaging and biopsy. Four exemplar patients showing continuous-wave Doppler
(maximum velocities >4m/s; Column 1), short axis cine stills demonstrating degrees of left ventricular hypertrophy (Cine; Column 2), matching late
gadolinium enhancement images (LGE, Column 3), matching extracellular volume fraction (ECV, Column 4), myocardial biopsy stained with picrosi-
rus red [collagen volume fraction (CVF), Column 5]. Patient A has minimal LVH, no LGE, an ECV of 28.4% and minimal biopsy subendocardial fibrosis
(CVF 4.6%). Patient B has concentric LVH, patchy non-infarct LGE, an ECV of 29.9% and moderate biopsy fibrosis (CVF 19.3%). Patient C has con-
centric LVH, widespread non-infarct LGE, an ECV of 36.5%, and severe biopsy fibrosis (CVF 24.5%). Patient D has mild concentric LVH, subtle suben-
docardial LGE (white arrow), an ECV of 24.5%, thickened endocardium, and subendocardial scarring. Scale bars (Columns 2–4) equal 5 cm.
4 T.A. Treibel et al.
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endocardium showed higher CVF than biopsies without endocar-
dium (15.0 ± 12% vs. 8.99 ± 6.7% P< 0.001; Figure 2). The endocar-
dium was thickened in AS patients due to collagen deposition in most
biopsies, with a mean endocardial thickness of 228 ± 129 microns vs.
40 ± 16 microns in the control samples (P< 0.001; Figure 3A).
Segmental analysis in tertiles of endocardium-containing biopsies (in
those structurally feasible; n= 40) revealed a decreasing gradient of fi-
brosis from the subendocardium towards the mid-myocardium
(20.4 ± 11.3% vs. 15.2 ± 8.7% vs. 13.0 ± 7.8%, P for trend= 0.001;
Figure 2). Of note, subendocardial fibrosis was caused predominantly
by microscars, whereas mid-myocardial fibrosis was due to interstitial
bands preferentially located around cardiomyocytes (Figure 3B).
Analysis of associations
Late gadolinium enhancement quantification correlated with CVF in
all samples (r2 = 0.248, P< 0.001), but this association was stronger in
endocardial containing samples (r2 = 0.501, P< 0.001; Figure 4). These
associations were independent of age, gender and history of CAD.
Figure 2 Biopsies with and without endocardium—presence of a gradient of fibrosis. (A) Collagen volume fraction in biopsies with and without en-
docardium. (B) Collagen volume fraction in samples with endocardium divided in tertiles. Box plots show the 5th and 95th (vertical lines), 25th and
75th (boxes), and 50th (horizontal line) percentile values for collagen volume fraction. (C) Representative images of three biopsies with endocardium
(left panel needle and middle and right panel scalpel). (D) Representative images of four biopsies without endocardium (needle).
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Collagen volume fraction quantification was weakly associated
with NT-proBNP (r2 = 0.055, P¼ 0.013) and hs-TnT (r2 = 0.072,
P< 0.01) levels in all patients. The correlation between CVF and NT-
proBNP improved slightly when we considered only the endocardial
samples (r2 = 0.123, P= 0.027). However, these associations were
lost when adjusting for confounding factors.
With regards to LV structure and function, both LGE and ECV
correlated weakly with LV end-diastolic volume index (LVEDVi;
r2 = 0.038, P= 0.026 and r2 = 0.066, P= 0.006, respectively), LV end-
systolic volume index (LVESVi; r2 = 0.067, P<_ 0.003 and r2 = 0.114,
P< 0.001, respectively) and left ventricular ejection fraction (LVEF)
(r2 = -0.055, P= 0.007 and r2 = -0.096, P= 0.001, respectively); but
the associations were only independent of confounding factors for
ECV. Late gadolinium enhancement was weakly but independently
correlated with LVMi (r2 = 0.087, P= 0.001); ECV was not (P¼ 0.06).
With regards to biomarkers, both LGE and ECV were independently
correlated with NT-proBNP (r2 = 0.212, P< 0.001 and r2 = 0.307,
P< 0.001, respectively; Figure 5A and B) and hs-TnT (r2 = 0.203,
P< 0.001 and r2 = 0.132, P< 0.001, respectively; Figure 5C and D).
Aortic stenosis valve severity did not associate with CVF, endo-
cardial thickness, LGE, ECV, NT-proBNP levels, or the degree of LV
remodelling. Of LGE, ECV, and CVF, only ECV correlated weakly
with the patient functional limitation (6MWT; r2 = -0.042, P¼ 0.040),
but this association was lost when adjusting for confounding factors.
To further evaluate the potential confounding effect of CAD, we
performed a sensitivity analysis by excluding patients with CAD and
we obtained the same results as with the adjusted multivariate linear
regression analysis.
Clinical and structural impact of late
gadolinium enhancement and
extracellular volume fraction
stratification
To compare LGE and ECV with clinical and structural parameters,
we dichotomized the variables (above and below median: 10.5 g for
LGE, 28.4% for ECV) with results shown in Table 2.
Patients with high vs. low LGE had more advanced LV remodelling
with higher LVESVi (P= 0.041), LVEDVi (P= 0.045), LV mass index
(P= 0.035), left atrial area index (LAAi) (P= 0.006), lower LVEF
(P= 0.032), more mitral regurgitation (P= 0.012), higher prevalence
of hypertension (P= 0.006), and CAD (P= 0.015). In accordance with
Figure 3 Patterns of fibrosis—endocardial thickening and myocardial microscars and interstitial fibrosis. (A) The endocardium in a control subject
(left panel) and in two aortic stenosis patients at the same magnification. The arrows show the endocardial thickness (green in normal, black in aortic
stenosis). (B) Higher magnification showing minimal subendocardial interstitial fibrosis in a control subject (left panel) and extensive microscars and
interstitial fibrosis in two aortic stenosis patients. Circles identify microscars and arrows diffuse fibrosis.
6 T.A. Treibel et al.
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the association analysis, these patients presented higher CVF values
(P< 0.001), NT-proBNP (P< 0.001), and hs-TnT (P= 0.001) levels.
Patients with high vs. low ECV also had greater LV remodelling
with increased LVEDVi (P= 0.012), LVESVi (P= 0.002), and lower
LVEF (P= 0.0031). Although the LAAi was not significantly different
(P¼ 0.08), diastolic function was worse (E/A, P= 0.022 and E/e’ ratio,
P¼ 0.018). Moreover, they also had an impaired 6MWT and a higher
New York Heart Association functional class. In accordance with the
association analysis, these patients presented higher NT-proBNP
(P< 0.001) and hs-TnT (P= 0.018) levels.
Combining LGE and ECV added value (Table 3). With increasing
abnormality in these parameters, cavity dimensions (LVEDVi, LVESVi,
and LAAi) increased, LVEF decreased, NT-proBNP and hs-TnT levels
increased, CVF increases, and patient functional capacity (6MWT)
decreased (P¼ 0.010). Interestingly, these changes were maintained
when we adjusted the analysis by the presence of CAD.
Discussion
In this, the largest prospective AS biopsy and multimodality imaging/bio-
marker study to date, the main findings are: (i) Histological assessment
of the myocardium in severe AS revealed complex morphology and to-
pography of fibrosis with three main patterns: thickened endocardium
with a massive fibrotic layer; a fibrosis gradient from the subendomyo-
cardium to the mid-myocardium with abundant microscopic scars; and
diffuse interstitial fibrosis. (ii) Neither histological collagen volume frac-
tion nor the CMR parameters ECV and LGE captured this fibrosis in its
totality. (iii) The combination of LGE and ECV identified better those
AS patients presenting with more adverse LV remodelling, more al-
tered blood biomarkers and histological parameters, and a more
reduced functional capacity than each parameter alone (Summarizing
Illustration). These findings were independent of the presence of CAD.
Biopsy findings
In the last 40 years, several studies have described MF as histological
hallmark of severe AS, documenting relevant clinical correlations and
an important prognostic role.3,18–21 However, these studies were
small and patient demographics have dramatically changed since the
early landmark studies in the 1970s and 80s (n 20, mean age 50,
predominantly male).18–21 Furthermore, the methodology of fibrosis
assessment has advanced since then. Our study used current histo-
logical techniques to systematically evaluate MF in severe AS not only
quantitatively but also morphologically and topographically in a large
cohort of patients reflecting the changing patients demographics in
AS (n= 133, mean age 70, 56% male).
We confirm the existence of a decreasing collagen gradient from
endocardium to the mid-myocardium in severe AS, supporting prior
studies.18,19 Importantly, the scalpel biopsies showed this better than
needle biopsies as they have higher yield of endocardium (needed to
orientate the sample).
The different patterns of collagen in severe AS may have different
pathogenic mechanisms and possible consequences. Most collagen
deposits exist as a thickened endocardial layer and subendocardial
scattered microfoci and trabecular fibrosis. Mid-myocardial fibrosis
appears as a diffuse network around cardiomyocytes and bundles.
The fibrosis gradient may be related to low-endocardial perfusion,19
thus reflecting a reparative response (i.e. replacement fibrosis) to is-
chaemia and subsequent cell loss. This is supported by previous find-
ings showing that reduced capillary density, in absolute terms as well
as in relation to the number of cardiomyocytes, accompanies MF in
patients with severe AS.22 On the other hand, the diffuse MF located
around cardiomyocytes may be reactive to pressure overload-
induced mechanical stimulation of local fibroblasts and to paracrine
factors produced by mechanically stressed (strain) cardiomyocytes
that, in turn, stimulate fibroblasts (i.e. reactive fibrosis).23
Cardiovascular magnetic resonance
findings
Cardiovascular magnetic resonance tissue characterization has devel-
oped over two decades, initially with the LGE technique for focal fi-
brosis,4–8 later with the ECV technique for diffuse fibrosis.9–12,24
Combined biopsy and CMR study are rare and limited by small sam-
ple size. Instead, myocardial tissue characterization in AS has been de-
scribed by presence or absence, and pattern of LGE (subendocardial
infarct-pattern vs. mid-wall non-infarct LGE). These histological find-
ings of thickened endocardium and a gradient of myocardial fibrosis
from endo- to epicardium suggest that these descriptive LGE pattern
need to be revisited, possibly by utilizing the latest motion-correction
or dark blood techniques.25
Here, LGE correlated with CVF (although the biopsy was obtained
from the basal anteroseptum which was not infarcted in any patient),
especially on endocardial biopsies (r2 = 0.5), which capture more of
the subendocardial microscars. The ECV was only mildly elevated
with broadly proportional increase in the cellular and extracellular
components of the myocardium (as observed by Schwarz et al.18 in
1978), and, unlike other papers, did not correlate with CVF.
Figure 4 Association of late gadolinium enhancement with colla-
gen volume fraction. Late gadolinium enhancement (LGE) quantified
in grams by a three standard deviation method correlated strongest
with collagen volume fraction (CVF) in endocardial containing sam-
ples (linear fit: y= 0.814xþ 3.109).
Reappraising myocardial fibrosis in severe aortic stenosis 7
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Figure 5 Associations of imaging and blood biomarkers. Late gadolinium enhancement (LGE) and extracellular volume fraction (ECV) correlated with
NT-proBNP (A and B) and with hs-TnT ( C and D) (linear fit: A y= 0.119x– 1.498; B y= 0.037xþ 0.103; C y= 0.025xþ 1.567; D y= 0.110xþ 1.008).
Summarizing Illustration This figure summarizes the main findings of the study.
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However, ECV did capture functionally important consequences,
given that patients with high ECV showed worse NT-ProBNP,
6MWT, and NYHA functional class.9–12,24 There are a number of
possible reasons for this discordance with other studies including the
underestimation of subendocardial microscar and fibrosis gradient
due to avoidance of the endo- and epicardium (for ECV we eroded
10% from the edge to avoid blood pool contamination); recruitment
of a less severe (more representative) phenotypes with less extensive
scarring (we recruited 50% of all AVR in our institution); reduced
capillary density (lower ECV) or compensatory vasodilatation (higher
ECV) may confound ECV measurements, which captures all extracel-
lular space including the intravascular plasma.26,27
We suspect that LGE is a marker of the reparative fibrotic re-
sponse to cardiomyocyte injury and loss. On the other hand, diffuse
.................................................................................. ..................................................................................
....................................................................................................................................................................................................................
Table 2 Patients stratified according to late gadolinium enhancement or extracellular volume median value
LGE ECV
<10.5 g (n5 65) >510.5 g (n566) P-value <28.4% (n5 58) >528.4% (n5 58) P-value
Age (years) 68.8 ± 10.4 71.7 ± 8.8 0.089 70.3 ± 10.0 70.1 ± 9.7 0.910
Gender (male/female) 28/37 45/21 0.004 34/24 31/27 0.575
BMI (kg/m2) 28.7 ± 5.5 28.2 ± 4.7 0.567 27.8 ± 5.0 29.3 ± 5.0 0.097
Comorbidities, n (%)
HTN 44 (68%) 56 (89%) 0.006 43 (75%) 49 (84%) 0.225
AF 6 (9%) 13 (20%) 0.089 7 (12%) 11 (19%) 0.305
CAD 14 (22%) 29 (45%) 0.015 19 (33%) 21 (36%) 0.746
Symptom, n (%)
Syncope 6 (9%) 4 (6%) 0.600 6 (10%) 4 (7%) 0.489
NYHA 0.721 0.040
I 8 (12%) 9 (14%) 8 (14%) 5 (9%)
II 33 (51%) 28 (42%) 34 (59%) 24 (41%)
III 17 (26%) 23 (35%) 13 (22%) 21 (36%)
IV 2 (3%) 2 (3%) 0 (0%) 4 (7%)
Chest pain 0.288 0.982
0 41 (63%) 39 (59%) 35 (60%) 37 (64%)
1 3 (5%) 7 (11%) 5 (9%) 5 (9%)
2 15 (23%) 8 (12%) 12 (21%) 10 (18%)
3 4 (6%) 5 (8%) 4 (7%) 5 (9%)
Valve type, bi/tri (n) 20/45 18/48 0.659 16/42 17/41 0.837
AVAi (cm2/m2) 0.41 ± 0.14 0.40 ± 0.13 0.605 0.42 ± 0.15 0.39 ± 0.11 0.384
Mean gradient (mmHg) 44.8 ± 11.9 47.8 ± 14.7 0.216 47.1 ± 14 44.8 ± 13 0.368
Mitral regurgitation (%) 7.4 ± 11.2 15.2 ± 14.3 0.012 9.1 ± 12.7 11.5 ± 12.9 0.428
EDVi (mL/m2) 63.2 ± 20.9 70.2 ± 21.9 0.045 61.0 ± 19.1 71.4 ± 24.7 0.012
ESVi (mL/m2) 19.0 ± 15.6 25.6 ± 20.7 0.041 16.9 ± 12.0 27.7 ± ± 23.3 0.002
LVMi (g/m2) 83.9 ± 27.5 90.7 ± 20.7 0.035 83.7 ± 24.4 91.8 ± 25.6 0.085
LVEF (%) 72.4 ± 13.2 67.1 ± 15.4 0.032 73.9 ± 11.4 65.6 ± 17.0 0.003
MAPSE (mm) 10.7 ± 3.5 9.8 ± 3.6 0.123 11.0 ± 3.2 9.53 ± 3.7 0.031
LAAi (cm2/m2) 12.7 ± 3.3 14.5 ± 4.2 0.006 12.8 ± 3.3 14.4 ± 4.6 0.081
E/A 0.91 ± 0.42 1.08 ± 0.58 0.084 0.87 ± 0.38 1.10 ± 0.59 0.022
DT (ms) 245 ± 69 227 ± 82 0.206 236 ± 72 237 ± 81 0.940
E/e’ 13.57 ± 6.28 13.94 ± 6.11 0.771 12.46 ± 6.27 14.94 ± 5.96 0.018
6MWT (m) 468 ± 190 412 ± 187 0.143 488 ± 145 393 ± 210 0.006
ECV (%) 27.5 ± 2.6 29.5 ± 2.8 <0.001 26.0 ± 1.7 30.7 ± 1.8 <0.001
LGE (g) 5.84 ± 2.5 22.8 ± 9.9 <0.001 11.5 ± 9.1 15.4 ± 12.2 0.090
CVF (%) 7.3 ± 4.7 15.7 ± 9.8 <0.001 10.4 ± 7.5 10.9 ± 8.5 0.707
NT-proBNP (pg/mL) 96 ± 139 277 ± 341 <0.001 99 ± 154 262 ± 335 <0.001
hs-TnT (ng/L) 15 ± 10 21 ± 20 0.001 15 ± 13 21 ± 18 0.018
Boldface values indicate statistically significant P-values.
Values are given as mean ± SD or n (and percentage).
LGE, late gadolinium enhancement; ECV, extracellular volume; BMI, body mass index; HTN, hypertension; AF, atrial fibrillation; CAD, coronary arterial disease; EDVi, end-dia-
stolic volume index; ESVi, end-systolic volume index; LVMi, left ventricular mass index; LVEF, left ventricular ejection fraction; MAPSE, mitral annular plane systolic excursion;
LAAi, left atrial area index; E, peak early velocity of the transmitral flow; A, peak late velocity of the transmitral flow; DT, deceleration time; E, peak early diastolic velocity of the
mitral annulus displacement; 6MWT, 6-minute-walk test; bi, bicuspid; tri, tricuspid; AVAi, aortic valve area index; CVF, collagen volume fraction; NT-proBNP, N-terminal pro-
brain natriuretic peptide; hs-TnT, high sensitivity troponin T; SD, standard deviation; NYHA, New York Heart Association.
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..reactive interstitial fibrosis is intimately linked to its local environment
and depends on cardiomyocyte function, strain and its interactions
with fibroblasts. Extracellular volume fraction may therefore be
more closely linked to the cardiomyocyte stress, and accordingly
could be considered more a measure of cardiomyocyte-interstitial
relationship than the current mainstream concept of ECV being a
pure interstitial marker.
Clinical impact
Myocardial fibrosis in severe AS has a characteristic pattern and dis-
tribution. When measuring MF by biopsy or CMR, location, sampling
and technical aspects of analysis matter. Invasive biopsy is limited by
size and sampling error, whereas LGE and ECV capture different re-
gions of myocardium and provide complementary information. Both
....................................................................................................................................................................................................................
Table 3 Patients stratified according to extracellular volume and late gadolinium enhancement combined
ECV2/LGE2 ECV2/LGE1 & ECV1/LGE2 ECV1/LGE1 P-value
(n5 37) (n5 46) (n532)
Age (years) 68.6 ± 11.0 71.4 ± 9.0 70.4 ± 9.8 0.421
Gender (male/female) 19/18 24/22 22/10 0.259
BMI (kg/m2) 28.3 ± 5.3 28.4 ± ± 5.4 29.0 ± 4.5 0.594
Comorbidities, n (%)
HTN 24 (65%) 38 (83%) 29 (91%) 0.041
AF 3 (8%) 7 (15%) 8 (25%) 0.243
CAD 7 (19%) 18 (39%) 14 (44%) 0.072
Symptom, n (%)
Syncope 5 (14%) 2 (4%) 3 (9.7%) 0.295
NYHA 0.125
I 5 (14%) 6 (13%) 2 (6%)
II 24 (65%) 17 (37%) 16 (50%)
III 16 (43%) 18 (39%) 10 (31%)
IV 0 (0%) 2 (4%) 2 (6%)
Chest pain 0.583
0 23 (62%) 27 (59%) 21 (66%)
1 2 (5%) 4 (9%) 4 (13%)
2 9 (24%) 9 (20%) 5 (16%)
3 1 (3%) 6 (13%) 2 (6%)
Valve type, bi/tri (n) 12/25 12/34 9/23 0.814
AVAi (cm2/m2) 0.42 ± 0.16 0.40 ± 0.12 0.39 ± 0.13 0.329
Mean gradient (mmHg) 45.2 ± 14.1 46.7 ± 11.2 45.8 ± 16.6 0.851
Mitral regurgitation (%) 6.8 ± 12.3 10.3 ± 11.4 15.1 ± 15.2 0.042
EDVi (mL/m2) 59.5 ± 20.8 66.8 ± 18.7 73.9 ± 27.2 0.008
ESVi (mL/m2) 15.5 ± 11.3 22.5 ± ± 17.1 30.5 ± 25.9 0.001
LVMi (g/m2) 81.8 ± 26.5 87.3 ± 26.1 95.7 ± 20.9 0.023
LVEF (%) 75.4 ± 9.4 69.0 ± 15.0 63.6 ± ± 17.4 0.001
MAPSE (mm) 11.3 ± 3.2 10.1 ± 3.5 9.2 ± 3.8 0.014
LAAi (cm2/m2) 12.4 ± 3.3 13.3 ± 3.1 15.6 ± 5.2 0.001
E/A 0.84 ± 0.26 0.97 ± 0.54 1.24 ± 0.63 0.004
DT (ms) 240 ± 68 243 ± 76 220 ± 88 0.364
E/e’ 13.09 ± 6.83 13.04 ± 5.47 15.60 ± 6.51 0.192
6MWT (m) 512 ± 136 420 ± 207 391 ± 188 0.010
ECV (%) 25.6 ± 1.6 28.7 ± 2.1 31.2 ± 1.9 <0.001
LGE (grams) 6.01 ± 2.48 12.64 ± 9.67 23.16 ± 11.22 <0.001
CVF (%) 7.84 ± 5.01 10.26 ± 8.03 14.45 ± 9.45 0.001
NT-proBNP (pg/mL) 60 ± 90 160 ± 189 342 ± 394 <0.001
hs-TnT (ng/L) 13.5 ± 14.5 17.5 ± 12.2 23.6 ± 20.4 0.012
Boldface values indicate statistically significant P-values.
Values are given as mean ± SD or n (and percentage).
LGE, late gadolinium enhancement; ECV, extracellular volume; BMI, body mass index; HTN, hypertension; AF, atrial fibrillation; CAD, coronary arterial disease; EDVi, end-dia-
stolic volume index; ESVi, end-systolic volume index; LVMi, left ventricular mass index; LVEF, left ventricular ejection fraction; MAPSE, mitral annular plane systolic excursion;
LAAi, left atrial area index; E, peak early velocity of the transmitral flow; A, peak late velocity of the transmitral flow; DT, deceleration time; E, peak early diastolic velocity of the
mitral annulus displacement; 6MWT, 6-minute-walk test; bi, bicuspid; tri, tricuspid; AVAi, aortic valve area index; CVF, collagen volume fraction; NT-proBNP, N-terminal of
pro-brain natriuretic peptide; hs-TnT, high sensitivity troponin T; NYHA, New York Heart Association.
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ECV and LGE track cardiomyocyte stress (NT-proBNP) and injury
(hs-TnT). Late gadolinium enhancement is known to track troponin
concentrations in AS which has been associated with advanced hy-
pertrophy, replacement fibrosis and outcome.28 Data on BNP vs.
ECV in AS are lacking. Blood biomarkers reflect ‘whole heart’ cardio-
myocyte stress and injury, but need to be interpreted in conjunction
with structural and functional parameters from non-invasive imaging,
as they can be elevated due to other causes. The imaging biomarkers
LGE and ECV offer global but also regional insights—asymmetrical
remodelling is common in AS and is associated with increased myo-
cardial injury, left ventricular decompensation, and adverse events.29
The combination of LGE and ECV—a multi-parametric approach—
better identified worse adverse LV remodelling, altered biochemical
and histological parameters, and functional capacity than each param-
eter alone. Timing of AVR is one of the challenges in AS, in particular
in asymptomatic patients. Recent focus has turned towards the com-
plex interplay between the degree of the valve stenosis, haemody-
namic load, and myocardial response. The combination of LGE and
ECV may prove to help in a better understanding of this interplay.
Strengths and limitations
This is the largest combined histology-multimodality imaging study in
AS, with even sub-groups larger than previous (n 20) histological
and combined studies.9–11,18–21 The analysis of the imaging and histo-
logical data was performed completely blinded by independent
groups. To make this study as applicable as possible, we recruited all-
comers (50% of all AVR for AS in our institution) rather than the se-
vere end of the spectrum and thereby included patient with CAD, hy-
pertension and diabetes. The effect of CAD was adjusted for as
detailed in the methods. Furthermore, the location of the biopsy
(basal anteroseptum) was never infarcted in this study. To achieve a
standardized biopsy procedure, all biopsies were obtained under di-
rect vision from the basal anteroseptum by a team of experienced
surgeons using either a scalpel or needle technique. Finally, we are
aware that alterations in other components of the myocardium (i.e.
cardiomyocytes and microvessels) also play a role in the myocardial
response to pressure overload and their impacts deserves to be eval-
uated in further studies.
Conclusion
Myocardial fibrosis in severe AS is complex with three main alter-
ations: endocardial thickening, subendocardial microscars, and diffuse
interstitial fibrosis. Neither histological collagen volume fraction nor
the CMR parameters ECV and LGE capture this fibrosis in its totality.
This study supports that the combination of invasive and non-invasive
techniques at scale is relevant to better characterize MF in severe AS
patients. Importantly, the combination LGE and ECV allows a better
phenotyping of AS patients according to their myocardial response
to AS in terms of MF and morphological and functional cardiac
alterations.
Supplementary material
Supplementary material is available at European Heart Journal online.
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